Recent business development activities strengthening our pipeline and platforms
Adding a one-time subretinal gene therapy that could transform care for geographic atrophy (GA), a leading cause of blindness
Potential 1st therapy with sustained efficacy for broad GA population
AAV-2 gene therapy inducing expression of CFI for treatment Compelling early preclinical & clinical data of GT005 with well tolerated safety profile
FDA Fast Track designation for GT005
相关推荐
热门下载
推荐
快速链接
热门标签
关注我们
扫码关注我们
了解更多相关信息